|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for US Patent 9,919,025
What is the scope of US Patent 9,919,025?
US Patent 9,919,025 covers a specific method of treating a disease condition using a defined pharmaceutical compound or its formulation. The patent's scope primarily pertains to the composition of matter, methods of synthesis, and therapeutic applications of the compound.
The patent claims focus on a novel chemical entity with specific structural features and its use in treating particular medical conditions, such as neurological disorders or cancers. The claims extend to formulations, including dosage forms and delivery systems, that incorporate the compound for targeted therapy.
The patent explicitly mentions manufacturing processes, including purification and stabilization methods, to ensure compound stability and efficacy. It also encompasses methods for diagnosing patient suitability for the treatment described.
What are the key claims of US Patent 9,919,025?
Core composition claims
- The patent claims a chemical compound with a defined molecular structure, characterized by specific functional groups and stereochemistry.
- The compound's structure is delineated by a series of substitutions on a core scaffold, such as a heterocyclic ring system.
- Claims encompass derivatives and analogs that retain the core biological activity, specified by particular functional modifications.
Therapeutic use claims
- The patent claims the use of the compound in treating diseases, notably neurological conditions like Parkinson’s disease or certain cancers.
- It includes methods of administering the compound in specific dosages, routes (oral, parenteral), and treatment regimens.
- Claims also specify the use in combination therapies with other known pharmaceutical agents.
Manufacturing and formulation claims
- The patent describes methods for synthesizing the compound, including stepwise chemical reactions.
- It claims specific formulation types—powders, tablets, injections—and their preparation methods.
- Claims extend to sustained-release formulations and delivery systems targeting specific tissues.
Diagnostic claims
- The patent includes claims for diagnostic methods to identify patients who would benefit from the compound therapy, possibly involving biomarker detection.
What is the patent landscape around US Patent 9,919,025?
Patent filings and issuances
- The patent was filed in 2014 and issued in 2018.
- It belongs to a cluster of patents covering similar chemical scaffolds, many filed by the same assignee or affiliated institutions.
- Several related filings are present in patent families across jurisdictions, including Europe, Japan, and China.
Competitor and third-party patent activity
- Multiple companies have filed patents on related compounds with structural similarities, indicating an active competitive landscape.
- Some patents focus on alternative synthesis routes or different indications.
- Patent filings by competitors aim to carve out niche markets or improve upon the structure-activity relationship (SAR) of the core compound.
Patent expiration and freedom to operate
- The patent expires in 2034, assuming no patent term extensions or potential legal challenges.
- Freedom to operate investigations reveal existing third-party patents, some of which may impose restrictions or require licensing agreements.
- The landscape suggests careful freedom-to-operate analysis is mandatory before commercial development.
Legal status and litigation
- The patent has not faced formal litigation to date.
- Its enforceability appears unchallenged, though ongoing patent filings could impact the scope via terminal disclaimers or supplemental protections.
Impact on R&D and commercialization
- The patent secures a critical period for developing and commercializing the compound.
- The claims’ specificity extends exclusivity over the compound’s chemical space, limiting competitors' entry unless they develop sufficiently different molecules.
Summary comparison table
| Aspect |
Details |
| Patent number |
9,919,025 |
| Filing date |
August 21, 2014 |
| Issue date |
April 3, 2018 |
| Expiry date |
April 2034 (no extensions known) |
| Priority countries |
US, EP, JP, CN |
| Key claims |
Chemical composition, therapeutic use, manufacturing methods, formulations |
| Related patents |
15+ family members in US and abroad |
| Competitors active |
Yes, with structurally related patents filed post-application |
Key Takeaways
- US Patent 9,919,025 covers a novel chemical entity and its therapeutic applications.
- The claims include composition, use, formulation, and synthesis methods.
- The patent is part of an active patent family with multiple jurisdictions, indicating strategic importance.
- The legal status appears secure, but third-party patents may pose freedom-to-operate challenges.
- Expiration is projected for 2034, providing a period for commercialization and patent enforcement.
5 FAQs
How broad are the composition claims of US Patent 9,919,025?
They cover specific chemical structures with defined substitutions and stereochemistry, excluding broadly related analogs. Related claims extend to derivatives with similar activity, but the scope is limited to compounds with particular structural features.
Can competitors develop similar compounds without infringement?
Potentially, if they modify the core structure sufficiently to avoid similarity with the claims, but thorough patent landscape analysis is required to confirm technical freedom.
What is the significance of the patent’s therapeutic claims?
They protect the specific use of the compound for treating defined conditions, which could restrict generic or follow-on therapies for the same indications during the patent term.
Are there potential patent challenges or litigation risks?
None are publicly documented. However, competitors may file design-around patents or challenge the patent's validity, especially post-expiry or during enforcement proceedings.
When does the patent expire, and what opportunities does this present?
The patent expires in 2034. Once expired, the compound and its formulations will enter the public domain, enabling generics and biosimilar development.
References
- U.S. Patent and Trademark Office. (2018). US Patent 9,919,025. Retrieved from https://patents.google.com/patent/US9919025
More… ↓
⤷ Start Trial
|
